Program leaders---cell and gene therapy

癌症细胞和基因治疗(CCGT)计划的目标是整合细胞学方面的进展 并将基因疗法应用于癌症的治疗。癌症中心计划是癌症中心计划的一个子组成部分 细胞和基因治疗中心，有来自贝勒多个部门的18名研究人员， 包括医学、儿科学、病理学、免疫学以及分子和人类遗传学。该计划 去年从NCI获得了总计6,315,268美元的支持，在同行评议中总共获得了18,522,146美元 资金问题。该计划的成员在同行评议的期刊上发表了180多篇与癌症有关的手稿 其中51%为方案内协作，30%为方案间协作。我们的研究 重点关注正常和恶性干细胞、癌症的过继免疫治疗和改善预后 干细胞移植治疗癌症的最新进展。CCGT由基础研究、转化研究和临床研究组成。我们的 基础研究人员致力于了解正常和恶性干细胞生长的机制 以及参与肿瘤血管发展的分子和细胞相互作用 和基质。这些研究人员还在确定免疫治疗的新靶点，并优化 将弱的肿瘤抗原呈递给免疫系统。我们的翻译调查员正在移动细胞 以及在一系列小规模迭代实验室-临床-从长凳到床边的基于基因的治疗- 实验室方案，并正在开发关键试验。我们有十年的历史， 成功和及时地实施了基因和细胞治疗方面的临床翻译项目，我们 有资源供应和测试所有需要的临床试剂，因为我们的中心是三个之一 国家NHLB1资助的细胞治疗中心生产援助。主要成就包括 病毒相关性肿瘤中病毒特异性细胞毒T淋巴细胞活性的研究(结果) 在用于治疗移植后淋巴瘤的EBV CTL的孤儿药物中)，以及显示抗肿瘤的研究 神经母细胞瘤和淋巴瘤患者中转基因T细胞的活性。我们的临床 研究人员运行成人和(与儿科肿瘤学计划合作)儿科造血 干细胞移植计划，并正在扩大移植治疗恶性肿瘤的适用性 单抗在亚消融预适应方案中的应用和移植后免疫治疗 减少GVHD，同时增强移植物抗肿瘤活性和重建抗病毒免疫。

The goals of the Cancer Cell and Gene Therapy (CCGT) Program are to incorporate advances in cellular and gene therapy into the treatment of cancer. The Cancer Center Program is a sub-component of the Center for Cell and Gene Therapy and has 18 research members from a multiple Departments at Baylor, including Medicine, Pediatrics, Pathology, Immunology and Molecular and Human Genetics. The program had a total of $6,315,268 support from the NCI last year and overall received $18,522,146 in peer reviewed funding. Members of the program published over 180 cancer related manuscripts in peer-reviewed journals of which 51% represented intraprogrammatic collaborations and 30% interprogrammatic. Our research focuses on normal and malignant stem cells, adoptive immunotherapy of cancer and on improving outcomes of stem cell transplantation for cancer. CCGT has basic, translational and clinical research components. Our basic investigators work on understanding the mechanisms by which normal and malignant stem cell growth is controlled, and on the molecular and cellular interactions involved in development of tumor vasculature and stroma. These researchers are also identifying new targets for immunotherapy, and optimizing presentation of weak tumor antigens to the immune system. Our translational investigators are moving cell and gene based therapies from the bench to the bedside in a series of small-scale iterative laboratory-clinical- laboratory protocols, and are also developing pivotal trials. We have a decade-long history of successful and timely implementation of clinical translational projects in gene and cellular therapy, and we have the resources to supply and test all the clinical reagents required, since our center is one of three national NHLBl-funded Production Assistance for Cellular Therapy centers. Major accomplishments include the demonstration of activity of virus specific cytotoxic T lymphocytes in virus-associated cancers (resulting in an orphan drug designation for EBV CTLs for post transplant lymphoma) and studies showing the antitumor activity of genetically modified T cells in subjects with neuroblastoma and lymphoma. Our clinical researchers run the adult and (in collaboration with the Pediatric Oncology program) pediatric hemopoietic stem cell transplant programs and are extending the applicability of transplantation for malignancy by using monoclonal antibodies in subablative conditioning regimens and using post transplant immunotherapy to reduce GVHD whilst augmenting graft versus tumor activity and reconstituting anti-viral immunity.